other primary study · 2016 · landmark
Not counted. An animal or lab study.
“Taken together, our data demonstrate that a single three-month regimen of rapamycin is sufficient to robustly increase life expectancy in middle-aged mice, comparable to the effects previously reported for life-long treatment, while also improving measures of healthspan and substantially altering the microbiome.”
Transient rapamycin treatment can increase lifespan and healthspan in middle-aged mice. Elife
Who: C57BL/6JNia mice aged 19-21 months from the NIA aged rodent colony
PMID 27549339